 |
|
agenda | presentations | speaker bios | registration | logistics | contact us |
Tentative Seminar Agenda*
| Thursday, March 8th |
| 8:00 a.m. |
Registration and continental breakfast |
| 9:00 a.m. |
Welcome |
| 9:15 a.m. |
Major Players, Corporate Strategies and Growth Forecasts in Oncology
Presenter: Kate Keeping |
| 9:45 a.m. |
Q&A |
| 10:00a.m. |
The Oncology Drug Pipeline: Will the Potential be Realized? Presenter: Joanne Graham, Ph.D. |
| 10:30 a.m. |
Q&A |
| 10:45 a.m. |
Break |
| 11:15 a.m. |
Estimating Commercially Relevant Cancer Patient Populations: Cancer Epidemiology Methods
Presenter: Michael Hughes, Ph.D. |
| 11:45 p.m. |
Q&A |
| noon |
Assessing Multinational Brands’ Share of Oncology Markets in the BRIC: What Defines Success?
Presenter: Kate Hohenberg |
| 12:30 p.m. |
Q&A |
| 12:45 p.m. |
Lunch |
| 2:00 p.m. |
Personalized Medicine: The Status Quo and Competitive Implications
Presenter: Michaela Miller, M.B.A. |
| 2:30 p.m. |
Q&A |
| 2:45 p.m. |
Break |
| 3:15 p.m. |
Zelboraf and Xalkori: Medical Oncologists Market Insights at Launch
Presenter: Dan Winkelman, M.Sc. |
| 3:45 p.m. |
Q&A
|
| 4:00 p.m. |
Biologics Market Dynamics: Payer and Physician Perception of Biosimilars in Oncology
Presenter: Andrew Merron, Ph.D. |
| 4:30 p.m. |
Q&A |
| 4:45 p.m. |
Wrap up and close |
| |
| *Agenda and timing are subject to change. |
The seminar will feature analysis from products from the following companies:

|
|
Thursday, March 8, 2012
8:00 a.m. – 5:00 p.m.
Palace Hotel
2 New Montgomery Street
San Francisco, CA
(415) 512-1111
http://www.sfpalace.com/
Welcome Reception: Wednesday, March 7th
Palace Hotel
6:00 p.m. – 9:00 p.m.

Testimonials
What Attendees Say About the Competitive Landscape Seminar Series:
"My first time attending a DR seminar. I'll definitely be back."
"I was very impressed with the quality of the information."
"Excellent clinical background made analysis highly credible."
"It was very valuable to hear different perspectives."
"Very insightful, ton of information"
"Great seminar! Thanks for preventing the typical 'vendor pitches'."
"Would definitely consider this meeting again." |